Code | CSB-RA021912A129phHU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
IHC | 1:50-1:200 |
IF | 1:20-1:200 |
The vectors expressing anti-SNCA antibody were constructed as follows: immunizing an animal with a synthesized peptide derived from human Phospho-SNCA (S129), isolating the positive splenocyte and extracting RNA, obtaining DNA by reverse transcription, sequencing and screening SNCA antibody gene, and amplifying heavy and light chain sequence by PCR and cloning them into plasma vectors. After that, the vector clones were transfected into the mammalian cells for production. The product is the recombinant SNCA antibody. Recombinant SNCA antibody in the culture medium was purified using affinity-chromatography. It can react with SNCA protein from Human and is used in the ELISA, IHC, IF.
SNCA is a protein-coding gene encoding Alpha-synuclein. Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. SNCA may function to integrate presynaptic signaling and membrane trafficking. According to some studies, SNCA may have the following characteristics.
SNCA variants are associated with an increased risk of multiple system atrophy. The SNCA and MAPT regions are the major genes whose common variants are influencing the risk of Parkinson's disease. Compared with LRRK2 and VPS35, SNCA mutation carriers had a younger age of onset. Autophagy regulation allows aged cells to escape SNCA-induced toxicity. SNCA-induced toxicity in aged cells is associated with selective degradation of mitochondria.
There are currently no reviews for this product.